Inhibrx Biosciences
INBX · NASDAQ
$95.30+$5.51 (+6.14%)TodayMarket closed ·
Prev close $89.79
Who owns INBX
Largest institutional holders, from their latest 13F filings
| Holder | Shares | % of shares |
|---|---|---|
| Viking Global Investors LP | 7.15M | 48.74% |
| RA Capital Management, LP | 4.72M | 32.20% |
| Perceptive Advisors LLC | 4.26M | 29.01% |
| Kayyem (Jon Faiz) | 3.27M | 22.32% |
| Lappe Mark | 3.05M | 20.76% |
| BlackRock Institutional Trust Company, N.A. | 2.47M | 16.85% |
| Eckelman (Brendan P) | 2.36M | 16.06% |
| Woodline Partners LP | 2.32M | 15.80% |
| The Vanguard Group, Inc. | 1.87M | 12.75% |
| TCG Crossover Management, LLC | 1.75M | 11.93% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| SPDR S&P Biotech ETF | 1.68M | 11.47% |
| Vanguard Total Stock Market Index Fund | 1.12M | 7.65% |
| iShares Russell 2000 ETF | 836.68K | 5.70% |
| Vanguard Extended Market Index Fund | 394.17K | 2.69% |
| Fidelity Small Cap Index Fund | 346.98K | 2.37% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $6.35M (20 trades) and sold $279.01K (5 trades) of INBX on the open market.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Lappe Mark | Buy | 100 | $8.58K |
| Lappe Mark | Buy | 2.45K | $208.33K |
| Lappe Mark | Buy | 2.45K | $205.89K |
| Lappe Mark | Buy | 100 | $8.58K |
| Lappe Mark | Buy | 2.47K | $209.95K |
| Lappe Mark | Buy | 2.47K | $207.65K |
| Lappe Mark | Buy | 3.00K | $305.11K |
| Lappe Mark | Buy | 1.50K | $148.32K |
| Lappe Mark | Buy | 2.18K | $216.73K |
| Lappe Mark | Buy | 3.32K | $328.63K |
Short interest
Settled Sep 30, 2026
- Shares short
- 3.43M
- Days to cover
- 11.82
- % of shares outstanding
- 23.40%
- Average daily volume
- 290.36K
- Change since last report
- +1.2%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.